NMD4C Knowledge Translation (KT) Webinar Series

Did you know? In September, the network’s Knowledge Translation team launched a  webinar series to provide a variety of information, tools and general guidelines to facilitate evidence-based practice.

If you missed the first KT webinar on September 29, it’s not too late! If you wish to watch (or re-watch) Dr. Lamontagne’s presentation ‘’Setting up the basics for a successful KT plan’’,  you can learn about the knowledge-to-action framework, including the differences between the end of grant and integrated KT plans, specific challenges with KT in the context of neuromuscular disease, and how to develop a KT plan for a CIHR- grant. You can still access a recording here.

 

Share your knowledge translation experience with us!

Did you recently apply KT skills in your clinical practice? Are you aware of any KT projects around you that you believe could benefit other colleagues? If you have an example of a successful (or constructive!) KT story, the NMD4C KT team would love to hear from you. We hope that sharing these experiences within the network can inspire other members of the neuromuscular community to explore the different KT options they have available to them, and to implement these strategies in their work.

If you would like to share a KT project with the network, please contact network communications coordinator James Davis at .

Useable_KT_updates

Read next...

2024 Dr David Green Award winners from MDC

NMD4C Receive Excellence in Service Delivery Award and Network Investigators Honored as part of Muscular Dystrophy Canada’s 2024 Dr David Green Awards

We are excited to share that the NMD4C has been awarded the Excellence in Service Delivery Award, one of the annual Dr David Green Awards presented by Muscular Dystrophy Canada.

NMD4C logo with text reading 'Canadian neuromuscular clinical trials network', MDC and IMHA logos at bottom.

NMD4C Launch Canadian Neuromuscular Clinical Trial Network

We are thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work.

Event organizers and participants from SMA outcome measures training, March 2024 in Quebec.

Training Session for Physiotherapists and Occupational Therapists on Outcome Measures in Spinal muscular atrophy hosted by Quebec SMA Network

This past March 23, the Quebec SMA Network (Réseau québécois de l’amyotrophie spinale – RQAS) in collaboration with the NMD4C and Muscular Dystrophy Canada (MDC) hosted an interactive training session for French-speaking physiotherapists and occupational therapists on assessment measures and practices for Spinal muscular atrophy (SMA). This training gathered clinicians to train and discuss SMA standardized outcome measures and work through current problems/challenges, to improve how these measures often tied to drug reimbursement are conducted. 

MDC award $900 000 towards clinical and translational research projects in 2024.

MDC Announce Recipients of 2024 Neuromuscular Clinical and Translational Research Grants

Muscular Dystrophy Canada (MDC) recently announced the recipients of its annual Neuromuscular Research Grants competition. Through these grants, MDC is investing $900,000 into clinical and translational research projects.

SMA outcome measures training graphic

SMA Outcome Measures Training for Physiotherapists and Occupational Therapists

To support the development and training on validated NMD outcome measures we are pleased to provide opportunities for physiotherapists and occupational therapists to attend training sessions for outcome measures.

Congratulations to the 2024 early career award winners. Dr Mireille Khacho and Dr Jean-Philippe Leduc Gaudet.

Congratulations to the 2024 NMD4C Early Career Awards Recipients

We are excited to announce the recipients of the 2024 NMD4C Early Career Awards! This is the second year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams.